JPRN-jRCTs041200048招募中未知
Certolizumab Pegol treatment with Reducing and stoppIng MEthotrexate in patients with Rheumatoid Arthritis in stable low disease activity-state - PRIMERA study
Asai Shuji0 个研究点目标入组 88 人开始时间: 2020年10月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients fulfilled the 1987 ACR classification criteria or the new ACR/EULAR diagnostic criteria for RA
- •2) RA patients with sustained low disease activity (CDAI <=10) for >=12 weeks while undergoing combination therapy with CZP plus MTX
- •3) RA patients receiving CZP, MTX, csDMARDs, and glucocorticoids at a stable dosage regimen for >=12 weeks prior to obtaining informed consent
- •4) RA patients aged >=20 years
- •5) Obtaining written informed consent
排除标准
- •1) Patients with adherence problems
- •2) Patients judged as inadequate at the discretion of inevstigators
研究者
相似试验
暂停
4 期
Continuation of certolizumab pegol with Or Without MTX in RA patients achieving sustained remissioN and low disease activityRheumatoid arthritisJPRN-jRCTs071190001Miyazaki Yusuke150
已完成
不适用
Efficacy and security of certolizumab pegol treatment in patients with reumatoid arthritisrheumatoid arthritisJPRN-UMIN000014486Saitama East Study Group100
进行中（未招募）
1 期
Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action.Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximabEUCTR2006-002027-16-GRCB AE50
已完成
不适用
Efficacy and safety of certolizumab pegol in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitorRheumatoid arthritisJPRN-UMIN000020154Saitama Medical University, Department of Rheumatology and Applied Immunology150
进行中（未招募）
1 期
Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled studyPrediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA)EUCTR2013-000337-13-PTniversitätsklinikum Erlangen156